UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 129

Sortiert nach

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

The Lancet (British edition), 2016-04, Vol.387 (10026), p.1415-1426

2016

Link zum Volltext

Verfügbarkeit prüfen

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

The European respiratory journal, 2017-08, Vol.50 (2), p.1700050-1700050

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

Journal of thoracic oncology, 2020-05, Vol.15 (5), p.860-866

2020

Link zum Volltext

Verfügbarkeit prüfen

On the relevance of a testing algorithm for the detection of ROS1 -rearranged lung adenocarcinomas

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.168-173

2014

Link zum Volltext

Verfügbarkeit prüfen

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort

Lung cancer (Amsterdam, Netherlands), 2021-12, Vol.162, p.119-127

2021

Link zum Volltext

Verfügbarkeit prüfen

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

British journal of cancer, 2019-02, Vol.120 (4), p.387-397

2019

Link zum Volltext

Verfügbarkeit prüfen

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice

The European respiratory journal, 2017-08, Vol.50 (2), p.1700514-1700514

2017

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9500-9500

2020

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Journal of clinical medicine, 2020-11, Vol.9 (12), p.3861

2020

Link zum Volltext

Verfügbarkeit prüfen

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial

Journal of clinical oncology, 2017-06, Vol.35 (18_suppl), p.LBA8507-LBA8507

2017

Link zum Volltext

Verfügbarkeit prüfen

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC

Targeted oncology, 2015-06, Vol.10 (2), p.247-253

2015

Link zum Volltext

Verfügbarkeit prüfen

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial

Journal of clinical oncology, , Vol.35 (15_suppl), p.LBA8507-LBA8507

Link zum Volltext

Verfügbarkeit prüfen

782-C Regulatory T-cell tumor infiltration is associated to better outcome in advanced NSCLC patients under ≥2nd line anti-PD1/L1 monotherapy in the PIONeeR project

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1813-A1813

2023

Link zum Volltext

Verfügbarkeit prüfen

The TAILOR study: To agree or to disagree?

Lung cancer (Amsterdam, Netherlands), 2014-06, Vol.84 (3), p.315-316

2014

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

The New England journal of medicine, 2018-05, Vol.378 (22), p.2093-2104

2018

Link zum Volltext

Verfügbarkeit prüfen

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

JTO clinical and research reports, 2020-09, Vol.1 (3), p.100068-100068, Article 100068

2020

Link zum Volltext

Verfügbarkeit prüfen

Development and Validation of a Simplified Prognostic Score in SCLC

JTO clinical and research reports, 2020-03, Vol.1 (1), p.100016-100016, Article 100016

2020

Link zum Volltext

Verfügbarkeit prüfen

P1.07-012 Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S702-S703

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(126)
Mit Volltextzugriff
(121)

Publikationsform

Artikel
(129)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(66)
Oncology
(60)
Humans
(53)
Life Sciences
(35)
Female
(31)
Male
(31)
Respiratory System
(31)
Aged
(28)
Lung Neoplasms - Drug Therapy
(28)
Lung Cancer
(25)
Middle Aged
(25)
Lung Neoplasms - Pathology
(24)
Chemotherapy
(21)
Lung Neoplasms - Genetics
(21)
Cancer
(19)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(19)
Adult
(17)
Mutation
(17)
Carcinoma, Non-Small-Cell Lung - Pathology
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

On the relevance of a testing algorithm for the detection of ROS1 -rearranged lung adenocarcinomas

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial

782-C Regulatory T-cell tumor infiltration is associated to better outcome in advanced NSCLC patients under ≥2nd line anti-PD1/L1 monotherapy in the PIONeeR project

460 Spatial distribution of infiltrating T lymphocytes with Immunoscore® CR T cells exhaustion test helps stratification of NSCLC patients treated with PD1/PDL1 inhibitors in the PIONeeR project

The TAILOR study: To agree or to disagree?

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

Development and Validation of a Simplified Prognostic Score in SCLC

P1.07-012 Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort

Suchergebnisse filtern